The Beta-2 Glycoprotein I Antibodies (IgG/IgM) test is a blood test used to detect autoantibodies that target Beta-2 Glycoprotein I, a protein in the blood that binds to phospholipids. These antibodies are part of the diagnostic evaluation for Antiphospholipid Syndrome (APS), and their persistent presence is associated with an increased risk of thrombosis (blood clot formation in veins or arteries) and pregnancy complications such as recurrent miscarriage, stillbirth, or preeclampsia.
Unlike anticardiolipin antibodies, anti-Beta-2 Glycoprotein I antibodies have greater specificity for diagnosing APS and are considered one of the main laboratory criteria for this syndrome. While these antibodies can also appear in other autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), a definitive diagnosis of APS requires a positive test result on two separate occasions at least 12 weeks apart, along with clinical symptoms (such as thrombosis or pregnancy complications).
The test is typically performed using ELISA (Enzyme-Linked Immunosorbent Assay), and the antibody levels (IgG/IgM) help assess the severity and prognosis of the disease. Test results should be interpreted cautiously, as false positives may occur during infections or transient inflammatory conditions. Timely identification of these antibodies is crucial for initiating preventive treatments (such as anticoagulants) and reducing the risk of life-threatening complications.
